plx4720

Overview

PLX4720 is a selective BRAF inhibitor used as a tool compound in preclinical research. It is structurally related to vemurafenib (PLX4032) and targets BRAF kinase, suppressing MAPK signaling in BRAF-mutant cells. PLX4720 is not an approved therapeutic agent; it is used in laboratory settings to model BRAF inhibitor pharmacology. (Corpus-grown; not confirmed in a canonical drug ontology — marked unverified.)

Evidence in the corpus

• In multiple myeloma cell line experiments, PLX4720 selectively suppressed MAPK signaling in the BRAF-K601N-mutant U266 cell line but paradoxically activated MAPK signaling in BRAF-WT, KRAS-G12A (MM1S) and NRAS-G12D (SKMM1) cell lines, predicting only partial clinical efficacy when BRAF mutations are subclonal within a KRAS/NRAS-co-mutated tumor PMID:24434212

Resistance mechanisms

• BRAF-WT MM cell lines with concurrent KRAS or NRAS mutations exhibit paradoxical MAPK upregulation upon PLX4720 exposure, suggesting that co-existing RAS mutations constitute an intrinsic resistance mechanism to single-agent BRAF inhibition PMID:24434212

Cancer types (linked)

• PCM — used in vitro to model BRAF inhibitor sensitivity in BRAF-mutant multiple myeloma

Sources

This page was processed by crosslinker on 2026-05-09.